Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04642469 · ClinicalTrials.gov registry record · Phase 3
Phase III Study to Determine Efficacy of Durvalumab in Stage II-III Non-small Cell Lung Cancer (NSCLC) After Curative Intent Therapy.
A Phase 3 study, sponsored by AstraZeneca.
- Completed
- Registry status
- Phase 3
- Development phase
- 30
- Enrollment target
NCT04642469 is a Phase 3 study that has completed, run by AstraZeneca. The registered enrollment target is 30 participants.
The verdict
NCT04642469, a Phase 3 study, has completed, sponsored by AstraZeneca.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 30 participants
- Enrollment target
Study Summary
This is a Phase III double-blind, placebo-controlled study of Durvalumab versus Placebo in patients with stage II-III NSCLC who are MRD-positive following curative intent therapy.
Interventions
- OTHER Placebo
- DRUG Durvalumab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2020-11-30 |
| Est. Completion | 2024-01-15 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04642469
The ClinicalTrials.gov registry entry for NCT04642469 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 30 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is AstraZeneca, which has 1,285 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT04642469 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04642469 about?
NCT04642469 is a clinical study titled "Phase III Study to Determine Efficacy of Durvalumab in Stage II-III Non-small Cell Lung Cancer (NSCLC) After Curative Intent Therapy.". This is a Phase III double-blind, placebo-controlled study of Durvalumab versus Placebo in patients with stage II-III NSCLC who are MRD-positive following curative intent therapy.
What is the current status of trial NCT04642469?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 30 participants. The study started on 2020-11-30. Estimated completion is 2024-01-15.
What interventions are being tested in trial NCT04642469?
The interventions under investigation include: Placebo (OTHER), Durvalumab (DRUG).
Who is sponsoring clinical trial NCT04642469?
This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.